Analysis of response to infliximab in ankylosing spondylitis according to the axial and/or peripheral involvement: autoantibodies and drop outs are more frequent in the peripheral subset

Ann Rheum Dis. 2007 Mar;66(3):427-8. doi: 10.1136/ard.2006.065052.
No abstract available

Publication types

  • Clinical Trial
  • Letter

MeSH terms

  • Adult
  • Antibodies, Monoclonal / therapeutic use*
  • Antirheumatic Agents / therapeutic use*
  • Autoantibodies / blood*
  • Biomarkers / blood
  • Humans
  • Infliximab
  • Middle Aged
  • Patient Dropouts
  • Spondylitis, Ankylosing / drug therapy*
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Autoantibodies
  • Biomarkers
  • Infliximab